Asset Details
Do you wish to reserve the book?
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Do you wish to request the book?
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
2016
Overview
A randomized trial suggests that patients with negative PET-CT findings after two cycles of ABVD may have the bleomycin dropped from the regimen for the final four cycles. The omission of bleomycin reduced pulmonary toxic effects without reducing overall survival.
The treatment of advanced-stage Hodgkin’s lymphoma with chemotherapy has produced high survival rates. A series of randomized trials has confirmed that doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), first described more than 40 years ago,
1
yields cure rates of 70 to 80%, similar to the rates observed with more complex multidrug regimens.
2
–
7
The possible exception is escalated therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP), with higher-than-standard doses of etoposide, doxorubicin, and cyclophosphamide.
8
This escalated regimen has been shown to yield higher progression-free survival rates than ABVD among previously untreated patients.
9
,
10
Trials in which ABVD and . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Bleomycin - administration & dosage
/ Cancer
/ Dacarbazine - therapeutic use
/ Doxorubicin - therapeutic use
/ Female
/ Hodgkin Disease - diagnostic imaging
/ Hodgkin Disease - drug therapy
/ Humans
/ Lymphoma
/ Male
/ Patients
/ Positron emission tomography
/ Survival
